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The antiviral activity of a CD81 cytotoxic T-lymphocyte (CTL) clone (TCC108) directed against a newly
identified HLA-B14-restricted epitope, human immunodeficiency virus type 1 (HIV-1) Rev(67-75) SAEPVP
LQL, was analyzed with respect to its kinetics of target cell lysis and inhibition of HIV-1 production. Addition
of TCC108 cells or CD81 reverse transcriptase-specific CTLs to HLA-matched CD41 T cells at different times
after infection with HIV-1 IIIB showed that infected cells became susceptible to CTL-mediated lysis before peak
virus production but after the onset of progeny virus release. When either of these CTLs were added to part
of the infected cells immediately after infection, p55 expression and virus production were significantly sup-
pressed. These data support a model in which CTLs, apart from exerting cytolytic activity which may prevent
continued virus release, can interfere with viral protein expression during the eclipse phase via noncytolytic
mechanisms. TCC108-mediated inhibition of virus replication in peripheral blood mononuclear cells caused
rapid selection of a virus with a mutation (69E3K) in the Rev(67-75) CTL epitope which abolished recognition
by TCC108 cells. Taken together, these data suggest that both cytolytic and noncytolytic antiviral mechanisms
of CTLs can be specifically targeted to HIV-1-infected cells.
Identification of immune responses that may limit progres-
sion toward AIDS and may eliminate infected cells that persist
despite effective antiviral therapy (6, 20, 30) is a major goal for
current research aimed at the development of vaccines and
immunotherapies against AIDS (1). It is generally assumed
that an effective vaccine against human immunodeficiency vi-
rus type 1 (HIV-1) should elicit an antiviral immune response
which includes virus-specific major histocompatibility complex
class I-restricted CD81 cytotoxic T lymphocytes (CTL), be-
cause their presence is associated with the control of primate
lentivirus replication and they have been detected in individ-
uals exposed to but apparently uninfected with HIV (reviewed
in reference 8). Furthermore, CTL have been shown to exert
pressure on virus replication in vivo (2, 9) and in vitro (3, 27,
32). CTL clones directed against the late viral proteins Gag,
reverse transcriptase (RT), and Env, have been shown to lyse
HIV-1-infected cells before peak virus production (31) and to
suppress HIV-1 replication in immortalized CD41 T-cell lines
such as H9 and T1 (32). Env-specific CTL have been shown to
eliminate HIV-1-infected CD41 peripheral blood mononu-
clear cells (PBMC) and H9 cells (32), indicating that inhibition
of HIV-1 replication involved cytolytic mechanisms. In addi-
tion to exerting cytolytic activity, HIV-specific CTL have been
shown to suppress virus replication by the excretion of soluble
factors (3, 32). Although CTL against late viral proteins do
exhibit antiviral activity, elimination of nonproductively in-
fected cells with still incomplete protein expression (18) and
suppression of low-level virus replication (20) may require
CTL directed against the regulatory viral proteins Tat and Rev.
These proteins are translated early in the replication cycle of
HIV-1 and are necessary for transcription (Tat) or expression
of the intermediate and late proteins (Rev) (14, 15). Consistent
with such a protective role of CTL against Rev and Tat, we
have shown previously that CTL with these specificities were
preferentially found in individuals who experienced a long-
term asymptomatic course of disease progression (28). In con-
trast, CTL responses against the late proteins Gag and RT did
not correlate with the rate of disease progression (28).
Here we present a detailed analysis of the Rev-specific CTL
response in one individual who has been infected for more
than 12 years without developing symptoms. Rev-specific CTL
clones were generated, and a minimal epitope as well as the
HLA class I restriction of its recognition were identified. It is
shown that both Rev- and RT-specific CTL can suppress
HIV-1 production before they exert cytolytic activity and that
Rev-specific CTL-mediated inhibition of virus replication in
PBMC leads to the rapid selection of virus mutated in the CTL
epitope.
MATERIALS AND METHODS
Cells. All cells were maintained in RPMI 1640 (BioWhittaker, Verviers, Bel-
gium) supplemented with L-glutamine (2 mM), penicillin (100 U/ml), strepto-
mycin (10 mg/ml), and 10% pooled human serum (R10H) for PBMC and T cells
or 10% fetal bovine serum (BioWhittaker) (R10F) for B-LCL cells. CTL clones
and the CD41 TCL2H7 cells were stimulated at 2-week intervals with phytohe-
magglutinin-L (PHA-L) (1 mg/ml; Boehringer Mannheim, Germany) and gam-
ma-irradiated (3,000 rads) allogenic feeder cells and maintained in R10H con-
taining recombinant interleukin-2 (rIL2) (50 U/ml; Eurocetus, Amsterdam, The
Netherlands). International Histocompatibility Workshop B-LCL cells were ob-
tained from the European Collection of Cell Cultures (Salisbury, United King-
dom).
Generation of CTL clones. HIV-1 Rev-specific T-cell lines obtained from
individual L709, HLA-A1,28;2B14,57, were seeded at 0.3, 1, and 3 cells per well
in 60-well Terasaki plates (Greiner, Alphen a/d Rijn, The Netherlands) in a final
volume of 20 ml per well containing PHA-L (1 mg/ml), rIL2 (50 U/ml), and
irradiated allogenic feeder cells. The plates were incubated at 37°C in a humid-
ified chamber with 5% CO2. After 10 to 14 days, growing cell cultures from plates
showing growth in 10 to 15% of wells were restimulated. Cell samples from these
cultures were analyzed for Rev-specific CTL activity on autologous B-LCL cells
* Corresponding author. Mailing address: Erasmus University Rot-
terdam, Institute of Virology, Room EE17-26, P.O. Box 1738, 3000
DR Rotterdam, The Netherlands. Phone: 31 10 4088066. Fax: 31 10
4365145. E-mail: Osterhaus@viro.fgg.eur.nl.
6851
infected with recombinant vaccinia virus (rVV) containing the HIV-1LAI rev gene
(TG4113; rVV-rev) in chromium release assays as described below. The Rev-
specific TCC108 clone expressed T-cell receptor VB14S1 uniformly (data not
shown), confirming its clonality. Since the five Rev-specific CTL clones were
restricted by the same HLA class I allele, recognized the same 20-mer peptide,
and were established from the same Rev-specific cell line, these clones most
likely originated from the same cell. For practical reasons, further analyses were
performed with one of these CTL clones, TCC108.
Chromium release assays. Target cells were labelled for 1 h with 100 mCi of
Na2 51CrO4 (Amersham, Buckinghamshire, United Kingdom), washed three
times, and adjusted to a concentration of 2 3 105 cells per ml in R5F. A volume
of 50 ml (104 cells) was plated in 96-well V-bottom plates. Effector cells were
added at ratios of between 3:1 and 10:1 in a final volume of 150 ml. The
spontaneous and maximum chromium releases were determined by the incuba-
tion of the target cells with R5F only or with 5% Triton X-100, respectively.
Triplicate incubations were performed in all assays. After incubation at 37°C for
4 h, supernatants were harvested with a harvesting device (Skatron, Oslo, Nor-
way), and radioactivity was counted in a gamma counter (LKBWallac, Turku,
Finland). The percent specific lysis was calculated as (experimental release 2
spontaneous release)/(maximum release 2 spontaneous release) 3 100. To en-
sure sufficient HIV-1-infected cells at each time point, TCL2H7 cells were
infected at a multiplicity of infection (MOI) of approximately 1.0.
Flow cytometry. The expression of CD4, CD8, and HLA-A2 was analyzed by
incubation of viable cells with CD4-fluorescein isothiocyanate (CD4-FITC) or
CD8-phycoerythrin (Becton Dickinson, Leiden, The Netherlands) or HLA-A2
specific monoclonal antibody BB7.2 (kindly provided by W. Biddison). FITC-
conjugated goat anti-mouse immunoglobulin (Becton Dickinson) was used as a
second antibody for detection of expression of HLA-A2. For detection of HIV-1
p55 expression, cells were incubated subsequentially with paraformaldehyde–
lyso-lecithin, cold absolute methanol, Nonidet P-40 (Sigma), and FITC- or
phycoerythrin-labelled anti-HIV-1 p55 monoclonal antibody (clone KC57)
according to the instructions of the manufacturer (Coulter, Mijdrecht, The
Netherlands).
Peptides. The 20-mer peptides with 10 residues of overlap, together spanning
the entire HIV-1 Rev sequence were kindly provided by H. Holmes (Medical
Research Council, South Mimms, Potters Bar, United Kingdom). For the prep-
aration of target cells, 0.5 3 106 to 1 3 106 B-LCL cells were incubated with
these peptides at 20 mM in 100 ml of R0. After 1 h, 900 ml of R5F was added and
cells were incubated overnight. The peptides used for fine mapping of the CTL
epitope recognized by TCC108 cells were manufactured at the European Vet-
erinary Laboratory (Woerden, The Netherlands). Chromium-labelled B-LCL
cells were incubated with these shorter peptides for 1 h at concentrations ranging
from 1 3 1029 to 3 3 1024 M, washed twice, and used as target cells.
Virus stocks. rVV-rev and rVV containing the polylinker without insert (186-
poly; rVV-control) were kindly provided by M. P. Kieny (Transge`ne, Strasbourg,
France). Stocks were prepared on RK13 cells and stored at concentrations of 1 3
108 to 3 3 108 PFU/ml at 270°C. For the preparation of rVV-infected target
cells, B-LCL cells were incubated with 10 PFU per cell at 107 cells per ml for 1 h.
Subsequently, the cells were diluted to 106/ml with R10F and incubated over-
night.
An HIV-1 IIIB stock was prepared on freshly infected PHA-activated CD41
TCC cells and stored at 270°C. The RT activity of this stock was 105 RT cpm/ml.
The infectious viral titer was determined by infection of PHA-activated PBMC or
TCL2H7 cells with serial fivefold dilutions of this stock in quadruplicate. With
both cell types an estimated titer of 105 infectious particles per ml was found.
RT assay. RT activity was assayed in a microassay as previously described by
Gregersen et al. (10) and adapted by Siebelink et al. (25). Culture supernatants
were precipitated with 32% polyethylene glycol 6000–1.5 M NaCl. The pellets
were resuspended in 15 ml of lysis buffer (50 mM Tris [pH 8.3], 20 mM dithio-
threitol, 0.25% Triton X-100) and mixed with 35 ml of H2O and 50 ml of RT
cocktail [100 mM Tris (pH 7.9), 150 mM KCl, 10 mM MgCl2, 4 mM dithiothre-
itol, 0.6 U of poly(rA)-oligo(dT), 60 mCi of [3H]TTP per ml]. After incubation at
37°C for 1 h, the DNA was precipitated with 20 ml of 120 mM Na4P2O7 z 10H2O
in 60% trichloroacetic acid for 15 min at 4°C. The DNA was harvested on glass
fiber filters with a Skatron cell harvester and washed with 12 mM Na4P2O7 z
10H2O in 5% trichloroacetic acid. The filters were dried at 80°C, and [3H]TTP
incorporation was measured in a beta scintillation counter (LKBWallac).
Kinetics of target cell recognition. Three days after their most recent stimu-
lation with PHA-L, 1.2 3 106 CD41 TCL2H7 cells were incubated with IIIB at
1.2 3 106 RT cpm (MOI of approximately 1) for 3 h at 37°C. The cells were
washed three times and cultured at 3 3 105 cells per ml in R10H supplemented
with rIL2 (50 U/ml). At various time points, a volume of 0.6 ml, including cells,
was harvested. After centrifugation, the supernatants were stored at 270°C for
RT assays, part of the cells were fixed for flow cytometric analysis of p55, CD4,
and CD8 expression, and part of the cells were labelled with chromium for
analysis in chromium release assays.
Coculture of CTL and acutely infected PBMC. PBMC (2 3 107) isolated from
a buffy coat were incubated with HIV-1 IIIB at 105 RT cpm for 3 h at 37°C. The
cells were washed three times and cultured at 5 3 106 cells per 10 ml of R10H
supplemented with PHA-L (1 mg/ml) and rIL2 (50 U/ml) in 25-cm2 flasks.
Effector cells were added at a ratio of 0.1:1. At various time points, 2 ml of the
culture was harvested and centrifuged (250 3 g). The supernatants were stored
at 270°C for analyses of RT activity and viral RNA sequences, and the cells were
fixed with paraformaldehyde–lyso-lecithin for flow cytometric analysis of HIV-1
p55, CD4, CD8, and HLA-A2 expression. At days 6 and 11 postinfection, part of
the cells were not fixed but were separated into a CD81 fraction and a CD82
fraction with an anti-CD8 monoclonal antibody covalently conjugated to mag-
netic beads (Becton Dickinson) according to the manufacturer’s instructions.
After treatment of the CD81 fraction with DetachaBead (Becton Dickinson)
and overnight incubation at 37°C, these cells were analyzed for cytolytic activity
against rVV-rev- and rVV-control-infected autologous B-LCL cells. CD81
PBMC could be discriminated from TCC108 and TCC112 cells by flow cytomet-
ric analysis of the expression of HLA-A2, which was present on the PBMC only.
Sequencing. Viral RNA was isolated from supernatants harvested from cul-
tures of HIV-1-infected PBMC with and without the Rev-specific TCC108 cells.
The second exon of rev was amplified by RT-PCR. After reverse transcription
with random primers, cDNA was amplified with primers GTACTTTCTATAG
TGAATAGAGTTAGGC and CCTATCTGTCCCCTCAGCTACT. PCR con-
ditions were as follows: 30 s at 95°C, 30 s at 50°C, and 30 s at 72°C for 30 cycles
and then 7 min of extension at 72°C. Amplified fragments were sequenced
directly on both strands by using the PCR primers with the Taq Dye Deoxy
Terminator sequencing kit on a 373A sequencing system from Applied Biosys-
tems (Foster City, Calif.). Sequences were analyzed with Geneworks (Intellige-
netics, Mountain View, Calif.).
RESULTS
HLA restriction and fine specificity of Rev-specific CTL
clones. To analyze the Rev-specific CTL response of a long-
term asymptomatic individual in more detail, we cloned a Rev-
specific T-cell line generated in a previous study from PBMC
of individual L709 (28). Five CD42 CD81 Rev-specific CTL
clones, TCC102, TCC104, TCC106, TCC108, and TCC110,
and one CD42 CD81 non-HIV-specific CTL clone, TCC112,
were obtained (Tables 1 and 2).
The HLA restriction of the Rev-specific CTL clones was de-
termined with a panel of partially HLA class I-matched B-LCL
cells infected with rVV-rev or rVV-control in standard chro-
mium release assays (Fig. 1A). All Rev-specific CTL clones
lysed the four rVV-rev-infected heterologous target cells
TABLE 1. Specificities of CD81 CTL clones from individual L709
CTL clone
% Specific lysisa
rVV-control rVV-rev
TCC102 1 6 3 61 6 5
TCC104 1 6 2 59 6 3
TCC106 0 6 0 86 6 9
TCC108 21 6 0 78 6 5
TCC110 0 6 1 79 6 5
TCC112 0 6 1 3 6 1
a Average (6 standard error; triplicates) percentages of CTL-mediated chro-
mium release by autologous rVV-infected B-LCL cells.
TABLE 2. Lysis of HIV-1 IIIB-infected cells by
CD81 T cells used in this studya
CD81
T-cell line
Specificity Effector/
target
ratio
% Specific lysis
(mean 6 SD)
Protein Epitope Mockinfection
HIV-1 IIIB
infection
TCC108 Rev SAEPVPLQL 10 5 6 4 48 6 6
3 0 6 3 37 6 1
TCC112 NDb ND 10 21 6 1 4 6 2
3 24 6 1 28 6 1
TCL1C11 RT IVLPEKDSW 10 21 6 1 63 6 8
3 21 6 1 62 6 9
a Target cells were CD41 TCL2H7 cells 10 days after mock or HIV-1 IIIB
infection (MOI of approximately 0.05).
b ND, not determined.
6852 VAN BAALEN ET AL. J. VIROL.
FIG. 1. HLA restriction and fine specificity of HIV-1 Rev-specific CTL clone TCC108. (A) Autologous and partially HLA class I-matched B-LCL cells were infected
with rVV-rev (filled bars) or rVV-control (open bars) and analyzed for recognition by TCC108 cells in a standard chromium release assay (upper panel). Additional
B-LCL cells were analyzed in a separate assay to confirm HLA-B14 restriction (lower panel). (B to D) Peptide-pulsed autologous B-LCL cells were analyzed for
recognition by TCC108 cells in standard chromium release assays. Chromium-labelled target cells were incubated overnight with one of the 11 20-mer peptides together
spanning the entire Rev sequence (B) or for 1 h with the N- and C-terminally truncated peptides before the addition of effector cells (C and D, respectively).
Effector-to-target ratios were between 3:1 and 10:1 in all assays. The average percent specific lysis (with standard error) for triplicates is shown. Results similar to those
presented in panels A and B were obtained with the Rev-specific CTL clones TCC102, TCC104, TCC106, and TCC110 (data not shown). The non-Rev-specific clone
TCC112 did not lyse any of the rVV-infected or peptide-pulsed target cells (data not shown).
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that shared HLA-B14 (Fig. 1A shows the results obtained
with TCC108 cells). Heterologous target cell lines that were
matched for HLA-A1 (four cell lines), HLA-A28 (three cell
lines), or HLA-B57 (three cell lines) were not lysed by the
Rev-specific CTL clones (Fig. 1A). These data indicate that
recognition of Rev by the CTL clones was restricted by HLA-
B14.
The location of the CTL epitope within the Rev protein was
estimated by using 11 20-mer peptides with 10 amino acid
residues of overlap, together spanning the entire Rev se-
quence. All five clones specifically lysed autologous B-LCL
cells pulsed with the peptide Rev(62-81) TYLGRSAEPVPLQ
LPPLERL but not those pulsed with the other peptides (Fig.
1B). Truncated peptides lacking the N-terminal residues 62T,
63Y, 64L, 65G, and 66R were recognized by TCC108 cells, but
those without 67S were not (Fig. 1C), indicating that 67S de-
fines the N terminus of the minimal epitope. TCC108 cells
recognized peptides truncated C terminally at 75L but not
peptides truncated at 74Q or 73L (Fig. 1D). These data show
that Rev(67-75) SAEPVPLQL is the minimal epitope recog-
nized by TCC108 cells. The amino acid arginine (R) has been
described to serve as an anchor at position 2 in HLA-B14
binding peptides (5), and it flanks the minimal epitope at po-
sition 66 of Rev. Titration of the peptides SAEPVPLQL, RSA
EPVPLQL, and GRSAEPVPLQL on autologous B-LCL cells
revealed that all three peptides required a concentration of at
least 1 mM to be recognized by TCC108 cells and showed a
similar increase in specific lysis with increasing concentrations
(Fig. 2). Thus, the additional residues 66R and 65G did not
contribute to the optimal recognition of the CTL epitope.
Kinetics of target cell lysis and suppression of HIV-1 pro-
duction by Rev- and RT-specific CTL. To evaluate the tempo-
ral relationship between protein expression in infected cells
and the antiviral activity of CTL, we compared the kinetics of
cytolysis of infected cells by CTL against the early protein
Rev (TCC108 cells) and by CTL against the late protein RT
[TCL1C11 cells; specific for RT(244-252) IVLPEKDSW in the
context of HLA-B57 (29)]. Both TCC108 and TCL1C11 cells
were shown to lyse an HIV-1 IIIB-infected CD41 T-cell line,
FIG. 2. Titration of peptides recognized by the Rev-specific clone TCC108.
Chromium-labelled autologous B-LCL cells were incubated with the peptide
Rev(65-75) GRSAEPVPLQL, Rev(66-75) RSAEPVPLQL, or Rev(67-75) SA
EPVPLQL for 1 h at the concentrations indicated. Subsequently, the target cells
were washed and cocultivated with TCC108 cells for 4 h. The effector-to-target
cell ratios were 10:1. The average percent specific lysis (with standard error) for
triplicates is shown. No lysis of B-LCL cells without peptide was observed (data
not shown).
FIG. 3. Kinetics of HIV-1 production and lysis of infected cells by Rev- and
RT-specific CTL. (A) CD41 TCL2H7 cells were infected as described in Mate-
rials and Methods, and culture supernatants were harvested at the indicated
times for analysis of virus production. The TCL2H7 cells were analyzed for p55
expression and for susceptibility to CTL-mediated lysis by Rev-specific clone
TCC108, RT-specific clone TCL1C11, and non-HIV-specific clone TCC112. The
effector-to-target ratios were 10:1. Lysis of uninfected CD41 TCL2H7 cells was
below 5% in all assays (data not shown). The chromium release data are plotted
as the average (with standard error) for triplicates at the time point at which the
chromium release assay was terminated, i.e., 6 hours after the addition of chro-
mium. This time was required for the chromium labelling (1 h), washing of the
target cells and preparing the cocultures of the effector and target cells (1 h), and
incubation (4 h). (B) p55 expression (closed symbols) and virus production (open
symbols) by TCL2H7 cells in the presence of TCC108 cells, TCL1C11 cells, or
TCC112 cells. Effector and target cells were discriminated by flow cytometric
analyses of CD8 and CD4 expression, respectively. The population of p55-
expressing TCL2H7 cells is expressed as a percentage of the CD82 cells and not
of the CD41 cells, since CD4 was down-regulated in a major fraction of the
infected cells. (C) Infected TCL2H7 cells were analyzed in chromium release
assays after incubation without peptide or with the relevant peptides at 10 mM:
SAEPVPLQL for TCC108 cells and IVLPEKDSW for TCL1C11 cells. The
average specific lysis (with standard error) for triplicates is shown. The dashed
line shows the percentage of p55-expressing cells at 48 h after infection. Lysis of
uninfected TCL2H7 cells without peptides was always below 5% (data not
shown), and peptide-pulsed uninfected TCL2H7 cells were lysed as efficiently as
peptide-pulsed infected cells (data not shown).
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TCL2H7, obtained from individual L709 (Table 2). At 12 h
after infection of TCL2H7 cells with HIV-1 IIIB (MOI of
approximately 1.0), no significant population of p55-expressing
cells was detected (Fig. 3A). The percentage of p55-expressing
cells increased slightly between 12 and 24 h and increased
rapidly thereafter: from 18% at 30 h to 50% at 36 h, 68% at
48 h, and 89% at 72 h. Significant virus production was found
at 30 h after infection, in agreement with previous reports on
the replication cycle of HIV-1 (14, 21), and production was
increased at 36, 48, and 72 h (Fig. 3A). These data indicate that
all cells expressing detectable levels of p55 at 48 h (here 68%
of the cells) had been infected by the initial inoculum. Since
Rev-encoding mRNA and Rev protein have been detected at
between 16 and 18 h after infection in IIIB-infected CD41 T
cells (14, 22), we expected to find significant specific lysis by
TCC108 cells added between 26 and 30 h or between 32 and
36 h after infection. Although the percentage of specific lysis
was higher at these time points than at 14 to 18 h, it did not
exceed 10% (Fig. 3A). At 38 to 42 h it was still only 15%, and
at 50 to 54 h it was 42%, reaching a maximum of 55% after 74
to 78 h (Fig. 3A). The RT-specific CTL lysed the infected cells
at similar levels and with similar kinetics as the Rev-specific
CTL (Fig. 3A). As expected, the infected cells were not lysed
by the non-HIV-specific TCC112 cells at any time (Fig. 3A). In
a parallel experiment, part of the infected TCL2H7 cells were
cocultured with the CTL immediately after infection. In cul-
tures containing TCC108 or TCL1C11 cells, p55 expression
and virus production were significantly suppressed at all times
(Fig. 3B). The presence of the TCC112 cells did not affect p55
expression or virus production (Fig. 3B).
That TCC108 and TCL1C11 cells were cytolytic at all time
points was verified in a separate assay: early after infection,
target cells loaded with the relevant synthetic peptides were
indeed lysed efficiently (Fig. 3C). Later, at 47 to 51 h, specific
lysis of infected cells not loaded with the peptides also was
observed (Fig. 3C), confirming the results shown in Fig. 3A.
Together these data indicate that infected cells cultured in
the absence of HIV-specific CTL are not susceptible to cytol-
ysis before they produce virus. Furthermore, they suggest that
mechanisms other than cytolysis caused the observed CTL-
mediated inhibition of virus production in the cocultures of
effector and target cells.
In vitro inhibition of HIV-1 replication by TCC108 cells.
Subsequently, we investigated the longevity of the TCC108-
mediated antiviral activity with freshly isolated PBMC. HLA-
B14-matched PBMC were infected with HIV-1 IIIB (MOI of
approximately 0.05) and cocultured with TCC108 cells or the
non-HIV-1-specific TCC112 cells for 11 days. The TCC-to-
CD4 cell ratio was 0.2 at the start of the experiment. Virus
production was detected in cultures without TCC108 cells on
days 6, 9, and 11 (Fig. 4A). In the coculture with TCC108 cells,
only a low level of RT activity was detected on day 9. On day
11 this level was similar to that in the control cultures. Flow
cytometric analyses showed that the number of TCC108 and
TCC112 cells increased 100-fold during the culture period
(Fig. 4B). Furthermore, CD81 cells, recovered from the cul-
ture containing TCC108 cells on days 6 and 11 by magnetic
bead selection, showed significant Rev-specific CTL activity
(Fig. 4C). These data indicate that the lack of control of virus
replication could not have been due to the disappearance of
the clone from the culture or to impairment of CTL function.
To test whether the virus had escaped CTL recognition by
mutation in the epitope, we sequenced the second exon of Rev
directly on the amplicons from the total virus pool produced in
the presence or absence of TCC108 cells. Sequencing was
performed on samples from day 11 only, since amplifications
carried out with earlier samples did not yield PCR products.
Only the virus from the coculture with TCC108 cells was found
to have a mutation, 69E3K, located in the third residue of the
minimal epitope recognized by TCC108 cells (Fig. 5). The
sequence signal was uniform, indicating that .90% of the virus
population contained the mutation. The mutant peptide SAK
PVPLQL was not recognized by TCC108 cells at concentra-
FIG. 4. Inhibition of HIV-1 replication by Rev-specific CTL. HLA-B14-ex-
pressing PBMC from an HIV-seronegative individual were infected with HIV-1
IIIB as indicated in Materials and Methods. PBMC (5 3 106) were cocultivated
without CTL, with 5 3 105 Rev-specific TCC108 cells, or with 5 3 105 non-HIV-
specific TCC112 cells. Both types of TCC cells had been stimulated 7 days before
addition to the PBMC. (A) Virus production was analyzed by quantification of
the RT activity in culture supernatants. The average RT activity (with standard
error) for triplicates is shown. (B) The fates of the CD41 PBMC and the CD81
TCC108 and TCC112 cells were determined by counting of the cells and flow
cytometric analysis of membrane-expressed CD4, CD8, and HLA-A2. HLA-A2
was included to discriminate between CD81 PBMC (expressing HLA-A2) and
the added TCC108 and TCC112 cells (both expressing HLA-A1 and -A28). (C)
CD81 cells were recovered from the cultures on days 6 and 11 by magnetic bead
selection and analyzed for Rev-specific CTL activity on autologous B-LCL cells
infected with rVV-rev or rVV-control. The average percent specific lysis (with
standard error) for triplicates is shown.
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tions ranging from 10 nM to 300 mM (data not shown), indi-
cating that the new virus was indeed an escape variant.
To assess whether escape from a Rev-specific CTL response
had occurred in vivo, we attempted to amplify the plasma virus
of individual L709 at different times after seroconversion.
Primers and PCR conditions were the same as for the ampli-
fication of the in vitro-cultured virus. However, no PCR prod-
ucts were obtained, most likely due to the low viral load in this
individual.
DISCUSSION
The fine specificity, kinetics of target cell lysis, and capacity
to inhibit HIV-1 replication of Rev-specific CTL from an in-
dividual infected with HIV-1 for more than 12 years without
developing symptoms were analyzed. CTL clones generated
from this individual’s PBMC recognized the 9-mer peptide
Rev(67-75) SAEPVPLQL as their minimal epitope in the con-
text of HLA-B14. The presence of residue L75 at position 9 is
consistent with the reported motif for HLA-B14 binding pep-
tides (5). Other predicted anchor residues were not present.
Two longer peptides containing a potential anchor, 66R, were
recognized at similar levels of efficiency as the minimal epi-
tope, indicating that this residue did not enhance presentation
to the CTL. Analysis of the interactions between HIV-1-spe-
cific CTL and HIV-1-infected target cells, i.e., immortalized
polyclonal CD41 T cells (TCL2H7 cells) infected with HIV-1
IIIB, showed target cell lysis by both Rev- and RT-specific
CTL. This indicates that their respective epitopes, as defined
by rVV and synthetic peptide analyses, were indeed generated
in these HIV-1-infected cells. The kinetics of Rev- and RT-
specific CTL-mediated cytolysis, first observed well before
peak virus production, indicate that CTL may prevent a sig-
nificant quantity of virus from being produced. This is in agree-
ment with the kinetics of Gag-, RT-, and Env-specific CTL-
mediated lysis of HIV-1-infected immortalized H9 and T1
cells, as reported by Yang et al., who sampled at 24, 48, 72, and
96 h after infection (31). As a result of frequent sampling
between 24 and 48 h after infection, we were able to extend
their findings by showing that infected cells, in the absence of
CTL, produce virus before they become susceptible to CTL-
mediated lysis. A peptide-pulsing experiment revealed that
limited target cell lysis during the first 42 h after infection could
not be explained by insufficient effector cell numbers or im-
paired effector cell function. Also, the possibility that limiting
antigen levels had affected the efficiency of cytolysis (26) is
probably not relevant for our system, considering the extent of
viral protein expression and virus production observed at 30 to
36 h after infection. The similarity in the kinetics of cytolysis
targeted at the early protein Rev and at the late protein RT
suggests that HIV-1 infection had interfered, transiently, with
a general aspect of the antigen processing and presentation
pathway. A 20 to 50% reduction of HLA class I surface ex-
pression after HIV-1 infection has been reported (13, 23, 31).
This down-regulation was shown to decrease cytolysis by HLA-
specific CTL (13, 23) but had no appreciable effect on the
capacity of infected cells to present synthetic peptides (31).
The latter finding is consistent with our observation that
TCL2H7 cells were susceptible to CTL-mediated lysis early
after infection when pulsed with the relevant peptides. The
presentation of endogenous epitopes, however, may be af-
fected when the intracellular expression of new HLA class I
molecules is impaired. Indeed, recently it has been shown that
HIV-1 Nef is involved in protecting infected cells from specific
CTL-mediated lysis by affecting the HLA class I surface ex-
pression (4). Also, other mechanisms, such as Tat-mediated
interference with the proteasome function (24), may have im-
peded the generation of HLA class I presentable peptides
early after infection.
If lysis of infected cells were the only inhibitory mechanism
of the CTL, one would expect a steady increase of the levels of
p55 expression and virus production by infected cells, even in
the presence of CTL, until the time at which they became
susceptible to CTL-mediated lysis. However, when the Rev- or
RT-specific CTL were added to the infected cells immediately
after infection, viral protein expression and virus production
were suppressed without delay during the entire coculture pe-
riod. These results suggest that early antiviral activity involved
noncytolytic mechanisms. Indeed, CD81 T cells have been
shown to inhibit HIV-1 replication by the production of solu-
ble factors (3, 16, 32), to inhibit hepatitis B virus gene expres-
sion by a noncytolytic mechanism (11), and to exert antiviral
effects against murine rotavirus and VV by perforin- and Fas-
independent mechanisms (7, 12). Because the Rev- and RT-
specific CTL were added to the target cells after infection,
factors that prevent binding or entry of HIV-1 could not have
been involved in the observed suppression of HIV-1 produc-
tion. It is possible that the suppression was mediated by CD81-
T-cell-derived factors that interfere with viral transcription,
like IL-16 (17, 33) or CD81 T-cell antiviral factor (16). If
noncytolytic antiviral mechanisms of TCC108 cells also con-
tributed to the observed suppression of viral replication in
HLA-B14-matched PBMC, they must have been specifically
targeted toward the infected cells expressing the appropriate
HLA epitope complex, since the replication of virus that had
escaped CTL recognition by a mutation in the HLA-B14-re-
stricted epitope was not significantly affected. Noncytolytic in-
terference with transcription and translation may, like cytoly-
FIG. 5. Sequence analysis of the second-exon Rev from virus cultured in the absence or presence of Rev-specific TCC108 cells. Viral RNA was isolated from culture
supernatants from the experiment shown in Fig. 4 on day 11 postinfection. The second-exon Rev sequences of virus cultured in the absence or presence of TCC108
cells are shown below the sequences of three known IIIB clones (19) for reference purposes. The CTL epitope region is in boldface.
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sis, require that CTL are targeted to infected cells via major
histocompatibility complex-epitope complexes, for this would
be a safeguard against harming bystander cells. To determine
the relative contributions of CTL against different proteins to
the control of viral replication, further characterization of (i)
CTL against late proteins with respect to their capacity to
inhibit viral replication, (ii) the affinities of the different epi-
topes for their HLA restriction elements, and (iii) the affinity
of each clone for its HLA peptide complex is required.
In summary, the present data show that CTL against early
and late viral proteins can lyse acutely HIV-1-infected cells
efficiently, but only after the production of progeny virus has
started. Yet, virus replication in freshly isolated PBMC was
significantly suppressed by CTL against the Rev protein, which
resulted in the rapid selection of CTL escape virus in vitro. It
is important to realize that the antiviral effect of CTL re-
sponses in vivo is determined by multiple factors, including the
breadth of the CTL response. Such factors will be difficult to
address in vitro with a limited set of CTL clones. However,
studies on the kinetics of viral protein-mediated interference
with target cell killing and on the relative contributions of CTL
against early and late viral proteins to the inhibition of viral
replication will shed new light on complications which the
immune system encounters in clearing virus and accordingly
may contribute to the development of vaccines and immuno-
therapies against AIDS.
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